Clareo Health | A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Adenocarcinoma of the prostate (as the predominant histology)
High-risk metastatic hormone-sensitive prostate cancer. High risk is defined as:
* Greater than or equal to (≥)4 bone metastases by bone scan and/or
* ≥1 visceral metastases by computed tomography or magnetic resonance imaging
Must have initiated androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or bilateral orchiectomy prior to randomization. Up to 3 months of ADT prior to randomization is permitted with or without first-generation anti-androgen.
Adequate organ function
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You may not be if
Prior treatment with abemaciclib or any other cyclin dependent kinase 4 and 6 (CDK4 \& 6) inhibitor
Development of metastatic prostate cancer in the context of castrate levels of testosterone
Received any prior systemic therapy for metastatic prostate cancer (including investigational agents), except for ADT and first-generation anti-androgen
Clinically significant cardiovascular disease as evidenced by myocardial infarction, arterial thrombotic events, or severe/unstable angina in the past 6 months, or New York Heart Association Class II to IV heart failure
History of syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin, or sudden cardiac arrest. Chronic and hemodynamically stable atrial arrhythmia well-controlled on medical therapy is permitted
Uncontrolled hypertension
Clinically active or chronic liver disease, moderate/severe hepatic impairment
